About Mirum Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://mirumpharma.com/
Frequently Asked Questions
What is the 52-week range for MIRM?
The 52-week high is $130 and the 52-week low is $63.232.
What is the P/E ratio for MIRM?
The P/E ratio data is currently unavailable.
What is the dividend yield for MIRM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -289.33%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -139.18%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 12.97.
Analyst Recommendation Trends
Wall Street analyst consensus for MIRM over the last few months:
Latest MIRM News
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile. The company
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data?
Mirum Pharmaceuticals (MIRM) stock is in focus after the company reported that brelovitug met the primary endpoint in the Phase 3 AZURE-1 trial for chronic hepatitis delta virus, supported by 48-week Phase 2b viral suppression data. Recent headlines around brelovitug and the FDA approval of Atebrioz have arrived after a softer patch for Mirum Pharmaceuticals, with the share price down 9.75% over 30 days and 24.87% over 90 days. Even though year to date the share price return is 12.67% and the...
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $123 to $130.
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta September 28, 2026 8:30...
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $195.
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
The U.S. Food and Drug Administration (FDA) on Friday approved Atebrioz (zilurgisertib) tablets, delivering a new once-daily oral treatment to patients suffering from fibrodysplasia ossificans progressiva (FOP). Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and Incyte Corporation (NASDAQ:INCY) announced the regulatory milestone, noting the medication helps reduce the volume of new abnormal bone formation in adults and children aged 12 and older. Read Also: Regeneron Secures FDA Approval For Ultra-Rar
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif., September 28, 2026--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta - Slideshow
2026-09-28. The following slide deck was published by Mirum Pharmaceuticals, Inc.
Mirum Pharma's Brelovitug Meets Phase 3 Primary Endpoint In AZURE-1 Study For Chronic Hepatitis Delta Virus
– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24– 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and increased rates of
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
FOSTER CITY, Calif., September 27, 2026--Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic HDV on September 28, 2026
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.
FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?
Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 10:45 AM EDTCompany ParticipantsChristopher...
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events
Mirum Pharmaceuticals is technically oversold but is likely to have more major drug pipeline catalysts occur in the coming months. Click for more on MIRM.
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst
Mirum nears an FOP launch Sept 26; PROGRESS data, small market risks, and brelovitug Phase 3 catalysts ahead.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., September 14, 2026--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 10:00 AM EDTCompany ParticipantsChristopher Peetz -...
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
FOSTER CITY, Calif., September 08, 2026--Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-14 | BJERKHOLT ERIC | -9,943 | $98.37 | $978,093 |
| 2026-09-11 | BJERKHOLT ERIC | -18,333 | - | - |
| 2026-09-11 | BJERKHOLT ERIC | +18,333 | - | - |
| 2026-09-02 | Howe Jolanda | -658 | $100 | $65,800 |
| 2026-09-01 | Peetz Christopher | -30,000 | - | - |
| 2026-09-01 | Peetz Christopher | -21,688 | $98.91 | $2,145,160 |
| 2026-09-01 | Peetz Christopher | -8,312 | $98.08 | $815,241 |
| 2026-09-01 | Peetz Christopher | +30,000 | $2.936 | $88,080 |
| 2026-08-18 | Howe Jolanda | -40,000 | - | - |
| 2026-08-18 | Howe Jolanda | -40,000 | $100 | $4,000,000 |
| 2026-08-18 | Howe Jolanda | +40,000 | $6.27 | $250,800 |
| 2026-08-11 | BJERKHOLT ERIC | -6,001 | $99.9016 | $599,510 |
| 2026-08-10 | Peetz Christopher | -20,000 | - | - |
| 2026-08-10 | Peetz Christopher | -2,300 | $100.14 | $230,322 |
| 2026-08-10 | Peetz Christopher | -6,017 | $99.25 | $597,187 |
| 2026-08-10 | Peetz Christopher | -11,683 | $98.51 | $1,150,892 |
| 2026-08-10 | Peetz Christopher | +20,000 | $2.936 | $58,720 |
| 2026-08-03 | Howe Jolanda | -1,840 | $105.29 | $193,734 |
| 2026-07-06 | Peetz Christopher | -20,000 | - | - |
| 2026-07-06 | Peetz Christopher | -1,710 | $124.79 | $213,391 |
| 2026-07-06 | Peetz Christopher | -1,975 | $123.74 | $244,387 |
| 2026-07-06 | Peetz Christopher | -4,181 | $122.34 | $511,504 |
| 2026-07-06 | Peetz Christopher | -12,134 | $121.65 | $1,476,101 |
| 2026-07-06 | Peetz Christopher | +20,000 | $2.936 | $58,720 |
| 2026-07-06 | BJERKHOLT ERIC | -300 | $124.94 | $37,482 |
| 2026-07-06 | BJERKHOLT ERIC | -528 | $123.84 | $65,388 |
| 2026-07-06 | BJERKHOLT ERIC | -1,048 | $122.43 | $128,307 |
| 2026-07-06 | BJERKHOLT ERIC | -3,124 | $121.67 | $380,097 |
| 2026-07-01 | Howe Jolanda | -2,721 | $120 | $326,520 |
| 2026-06-15 | Ramasastry Saira | +1,980 | - | - |
| 2026-06-15 | Ramasastry Saira | +3,772 | - | - |
| 2026-06-15 | Fischer Laurent | +1,980 | - | - |
| 2026-06-15 | Fischer Laurent | +3,772 | - | - |
| 2026-06-15 | Brege Laura | +1,980 | - | - |
| 2026-06-15 | Brege Laura | +3,772 | - | - |
| 2026-06-15 | Heron Patrick J | +1,980 | - | - |
| 2026-06-15 | Heron Patrick J | +3,772 | - | - |
| 2026-06-15 | Walbert Timothy P | +1,980 | - | - |
| 2026-06-15 | Walbert Timothy P | +3,772 | - | - |
| 2026-06-15 | GREY MICHAEL G | +1,980 | - | - |
| 2026-06-15 | GREY MICHAEL G | +3,772 | - | - |
| 2026-06-09 | BJERKHOLT ERIC | -2,393 | - | - |
| 2026-06-09 | BJERKHOLT ERIC | +2,393 | $26.49 | $63,391 |
| 2026-06-08 | BJERKHOLT ERIC | -1,567 | $95.12 | $149,053 |
| 2026-06-08 | BJERKHOLT ERIC | -1,175 | $93.95 | $110,391 |
| 2026-06-08 | BJERKHOLT ERIC | -2,258 | $92.84 | $209,633 |
| 2026-06-05 | Radovich Peter | -16,988 | - | - |
| 2026-06-05 | Radovich Peter | +16,988 | $19.19 | $326,000 |
| 2026-06-01 | Peetz Christopher | -30,000 | - | - |
| 2026-06-01 | Peetz Christopher | -883 | $99.66 | $88,000 |
| 2026-06-01 | Peetz Christopher | -1,021 | $98.2 | $100,262 |
| 2026-06-01 | Peetz Christopher | -1,973 | $97.56 | $192,486 |
| 2026-06-01 | Peetz Christopher | -6,926 | $96.15 | $665,935 |
| 2026-06-01 | Peetz Christopher | -16,595 | $95.34 | $1,582,167 |
| 2026-06-01 | Peetz Christopher | -2,602 | $94.64 | $246,253 |
| 2026-06-01 | Peetz Christopher | +30,000 | $2.936 | $88,080 |
| 2026-06-01 | Ramasastry Saira | -3,977 | $100 | $397,700 |
| 2026-05-29 | Cardon Lon | -3,977 | - | - |
| 2026-05-29 | Cardon Lon | +3,977 | - | - |
| 2026-05-29 | Ramasastry Saira | -3,977 | - | - |
| 2026-05-29 | Ramasastry Saira | +3,977 | - | - |
| 2026-05-29 | Fischer Laurent | -3,977 | - | - |
| 2026-05-29 | Fischer Laurent | +3,977 | - | - |
| 2026-05-29 | Walbert Timothy P | -3,977 | - | - |
| 2026-05-29 | Walbert Timothy P | +3,977 | - | - |
| 2026-05-15 | Ramasastry Saira | -2,000 | - | - |
| 2026-05-15 | Ramasastry Saira | -2,000 | $109.47 | $218,940 |
| 2026-05-15 | Ramasastry Saira | +2,000 | $23.51 | $47,020 |
| 2026-04-15 | Ramasastry Saira | -2,000 | - | - |
| 2026-04-15 | Ramasastry Saira | -2,000 | $96.9 | $193,800 |
| 2026-04-15 | Ramasastry Saira | +2,000 | $23.51 | $47,020 |
| 2026-03-16 | Howe Jolanda | -4,732 | $91.9779 | $435,239 |
| 2026-03-16 | Quan Joanne | -7,287 | $91.9779 | $670,243 |
| 2026-03-16 | Radovich Peter | -16,515 | $91.9779 | $1,519,015 |
| 2026-03-16 | Peetz Christopher | -40,985 | $91.9779 | $3,769,714 |
| 2026-03-16 | Ramasastry Saira | -2,000 | - | - |
| 2026-03-16 | Ramasastry Saira | -2,000 | $90.76 | $181,520 |
| 2026-03-16 | Ramasastry Saira | +2,000 | $23.51 | $47,020 |
| 2026-03-16 | BJERKHOLT ERIC | -7,287 | $91.9779 | $670,243 |
| 2026-03-15 | Howe Jolanda | -6,000 | - | - |
| 2026-03-15 | Howe Jolanda | -2,658 | - | - |
| 2026-03-15 | Howe Jolanda | +6,000 | - | - |
| 2026-03-15 | Howe Jolanda | +2,658 | - | - |
| 2026-03-15 | Quan Joanne | -13,334 | - | - |
| 2026-03-15 | Quan Joanne | +13,334 | - | - |
| 2026-03-15 | Radovich Peter | -23,000 | - | - |
| 2026-03-15 | Radovich Peter | -7,220 | - | - |
| 2026-03-15 | Radovich Peter | +23,000 | - | - |
| 2026-03-15 | Radovich Peter | +7,220 | - | - |
| 2026-03-15 | Peetz Christopher | -50,000 | - | - |
| 2026-03-15 | Peetz Christopher | -25,000 | - | - |
| 2026-03-15 | Peetz Christopher | +50,000 | - | - |
| 2026-03-15 | Peetz Christopher | +25,000 | - | - |
| 2026-03-15 | BJERKHOLT ERIC | -13,334 | - | - |
| 2026-03-15 | BJERKHOLT ERIC | +13,334 | - | - |
| 2026-03-06 | Radovich Peter | -5,912 | - | - |
| 2026-03-06 | Radovich Peter | +5,912 | $15.87 | $93,823 |
| 2026-02-13 | Ramasastry Saira | -2,000 | - | - |
| 2026-02-13 | Ramasastry Saira | -2,000 | $102.09 | $204,180 |
| 2026-02-13 | Ramasastry Saira | +2,000 | $23.51 | $47,020 |
| 2026-02-02 | Howe Jolanda | -968 | $103.3035 | $99,998 |
| 2026-02-02 | Radovich Peter | -2,631 | $103.3035 | $271,792 |
| 2026-02-02 | Peetz Christopher | -9,108 | $103.3035 | $940,888 |
| 2026-01-31 | Howe Jolanda | -1,771 | - | - |
| 2026-01-31 | Howe Jolanda | +1,771 | - | - |
| 2026-01-28 | Howe Jolanda | +9,000 | - | - |
| 2026-01-28 | Howe Jolanda | +4,970 | - | - |
| 2026-01-28 | Howe Jolanda | +7,680 | - | - |
| 2026-01-28 | Quan Joanne | +20,000 | - | - |
| 2026-01-28 | Quan Joanne | +11,760 | - | - |
| 2026-01-28 | Quan Joanne | +18,140 | - | - |
| 2026-01-28 | Radovich Peter | +34,500 | - | - |
| 2026-01-28 | Radovich Peter | +16,280 | - | - |
| 2026-01-28 | Radovich Peter | +25,120 | - | - |
| 2026-01-28 | Peetz Christopher | +75,000 | - | - |
| 2026-01-28 | Peetz Christopher | +43,500 | - | - |
| 2026-01-28 | Peetz Christopher | +67,000 | - | - |
| 2026-01-28 | BJERKHOLT ERIC | +20,000 | - | - |
| 2026-01-28 | BJERKHOLT ERIC | +11,760 | - | - |
| 2026-01-28 | BJERKHOLT ERIC | +18,140 | - | - |
| 2026-01-26 | Howe Jolanda | -842 | $96.192 | $80,994 |
| 2026-01-26 | Radovich Peter | -3,143 | $96.192 | $302,331 |
| 2026-01-26 | Peetz Christopher | -6,831 | $96.192 | $657,088 |
| 2026-01-26 | BJERKHOLT ERIC | -1,053 | $96.192 | $101,290 |
| 2026-01-23 | Howe Jolanda | -1,500 | - | - |
| 2026-01-23 | Howe Jolanda | +1,500 | - | - |
| 2026-01-23 | Radovich Peter | -5,750 | - | - |
| 2026-01-23 | Radovich Peter | +5,750 | - | - |
| 2026-01-23 | Peetz Christopher | -12,500 | - | - |
| 2026-01-23 | Peetz Christopher | +12,500 | - | - |
| 2026-01-23 | Heron Patrick J | +131,425 | $68.48 | $8,999,984 |
| 2026-01-23 | Heron Patrick J | +159,277 | - | - |
| 2026-01-23 | BJERKHOLT ERIC | -2,667 | - | - |
| 2026-01-23 | BJERKHOLT ERIC | +2,667 | - | - |
| 2026-01-22 | Howe Jolanda | -926 | $93.3252 | $86,419 |
| 2026-01-22 | Quan Joanne | -1,822 | $93.3252 | $170,039 |
| 2026-01-22 | Radovich Peter | -2,382 | $93.3252 | $222,301 |
| 2026-01-22 | Peetz Christopher | -7,098 | $93.3252 | $662,422 |
| 2026-01-22 | BJERKHOLT ERIC | -1,421 | $93.3252 | $132,615 |
| 2026-01-21 | Howe Jolanda | -1,542 | - | - |
| 2026-01-21 | Howe Jolanda | +1,542 | - | - |
| 2026-01-21 | Quan Joanne | -3,334 | - | - |
| 2026-01-21 | Quan Joanne | +3,334 | - | - |
| 2026-01-21 | Radovich Peter | -4,167 | - | - |
| 2026-01-21 | Radovich Peter | +4,167 | - | - |
| 2026-01-21 | Peetz Christopher | -12,797 | - | - |
| 2026-01-21 | Peetz Christopher | +12,797 | - | - |
| 2026-01-21 | BJERKHOLT ERIC | -3,334 | - | - |
| 2026-01-21 | BJERKHOLT ERIC | +3,334 | - | - |
| 2026-01-20 | Quan Joanne | -6,911 | $90.2696 | $623,853 |
| 2026-01-16 | Quan Joanne | -12,500 | - | - |
| 2026-01-16 | Quan Joanne | +12,500 | - | - |
| 2026-01-15 | Ramasastry Saira | -2,000 | - | - |
| 2026-01-15 | Ramasastry Saira | -2,000 | $90.99 | $181,980 |
| 2026-01-15 | Ramasastry Saira | +2,000 | $23.51 | $47,020 |
| 2025-12-31 | Peetz Christopher | -21,070 | - | - |
| 2025-12-22 | Ramasastry Saira | -5,000 | - | - |
| 2025-12-22 | Ramasastry Saira | -5,000 | $80 | $400,000 |
| 2025-12-22 | Ramasastry Saira | +5,000 | $23.51 | $117,550 |
| 2025-12-19 | GREY MICHAEL G | -50,000 | - | - |
| 2025-12-19 | GREY MICHAEL G | -50,000 | $78 | $3,900,000 |
| 2025-12-19 | GREY MICHAEL G | +50,000 | $2.936 | $146,800 |
| 2025-12-18 | Ramasastry Saira | -2,000 | - | - |
| 2025-12-18 | Ramasastry Saira | -1,000 | $70 | $70,000 |
| 2025-12-18 | Ramasastry Saira | -1,000 | $69.46 | $69,460 |
| 2025-12-18 | Ramasastry Saira | +2,000 | $23.51 | $47,020 |
| 2025-12-01 | GREY MICHAEL G | -50,000 | - | - |
| 2025-12-01 | GREY MICHAEL G | -50,000 | $74 | $3,700,000 |
| 2025-12-01 | GREY MICHAEL G | +50,000 | $2.936 | $146,800 |
| 2025-11-21 | GREY MICHAEL G | -50,000 | - | - |
| 2025-11-21 | GREY MICHAEL G | -50,000 | $70 | $3,500,000 |
| 2025-11-21 | GREY MICHAEL G | +50,000 | $2.936 | $146,800 |
| 2025-11-18 | Peetz Christopher | -19,133 | - | - |
| 2025-11-18 | Peetz Christopher | +19,133 | $19.24 | $368,119 |